

Observations: 306

Variables: 73

Note: Unless otherwise indicated, blank fields indicate missing values

List of Variables and Attributes

#	Variable Name	Type	Variable Label	Variable Codes
1	uid	Num	Patient ID Number (blinded)	
2	ps	Num	ECOG Performance Status	0 = 'Fully active' 1 = 'Restricted in Physically Strenuous Activity' 2 = 'Ambulatory and Capable of Self Care'
3	ser_hvy_chain	Num	Serum Heavy Chain	1='IgG' 2='IgA' 3='IgM' 4='IgD' 5='IgE' 6='Biclonal' -1='Unknown' -9 = ' Not Applicable'
4	ser_ife_m_protn	Num	Serum M Immuno-fixation Electrophoresis (IFE)	1 = 'No' 2 = 'Yes'
5	ser_lgt_chain	Num	Serum Light Chain	1 = 'Kappa Light Chain' 2 = 'Lambda Light Chain' -1 = 'Unknown' -9 = ' Not Applicable'
6	ser_tot_protn_rs	Num	Serum M-protein (g/dL)	
7	arm	Char	Assigned Treatment Arm	'A'='MPT-T' 'B'='MPR-R'
8	sex	Num	Gender	1 = 'Male' 2 = 'Female'
9	age*	Num	Age in Years (capped at 90)	
10	age65oc	Num	Age65 (for Table 1)	0='Age<65' 1='Age>=65'
11	age75oc	Num	Age75 (for Table 1)	0='Age<75' 1='Age>=75'
12	c4death	Num	OS Censoring Status	0 = 'Event' 1 = 'Censored'
13	t2death	Num	OS: Time to Death in Months	
14	t2pfs1	Num	PFS: Time to Progression in Months	
15	c4pfs1	Num	PFS Censoring Status	0 = 'Event' 1 = 'Censored'
16	total_period_m	Num	Overall Treatment Duration	
17	main_period_m	Num	Maintenance Treatment Duration	-9 = ' Not Applicable'
18	inMAIN	Num	In Maintenance Therapy	1 = 'Yes, in Maintenance Therapy' -9 = ' Not Applicable'
19	SP_RESP	Num	Investigator-Adjudicated Response	1='CR' 2='PR' 4='SD' 5='PD' 6='UNEVAL' 7='VGPR'
20	ONTX_flag	Num	On Treatment Indicator	0='Off Treatment' 1='On Treatment'
21	notx	Num	Did NOT Receive Protocol Treatment	0='Tx Pop' 1='Not Tx-Out'
22	age_strat	Num	Age strata at randomization (Strat. factor I)	1='Age<65' 2='Age>/=65'
23	iss_strat	Num	International Staging System [ISS] strata at randomization (Strat. factor II)	1='ISS I-II' 2='ISS III'
24	iss_stage	Num	ISS Stage	1='ISS I' 2='ISS II' 3='ISS III'
25	creat_hi	Num	High Creatinine	0='creat<=1.5' 1='creat>1.5'
26	hgb_hi	Num	High Hemoglobin	0='hgb<=11' 1='hgb>11'
27	b2m_hi	Num	High B2M	0='B2M < 3.5' 1='B2M >= 3.5'
28	ps_bin	Num	PS Bin	1='PS0-1' 2='PS2'
29	race2cat	Num	Race White vs Others	0= 'White' 1= 'Non-White'

30	PRresp_SP	Num	Centrally-Adjudicated Partial Response (PR)	1 = 'No' 2 = 'Yes'
31	VGPRresp_SP	Num	Centrally-Adjudicated Very Good PR (VGPR)	1 = 'No' 2 = 'Yes'
32	PRresp_updt	Num	Per-Protocol Partial Response (PR)	1 = 'No' 2 = 'Yes'
33	VGPRresp_updt	Num	Per-Protocol Very Good PR (VGPR)	1 = 'No' 2 = 'Yes'
34	classSPM	Num	Class of Second Primary Metastases	1='Heme SPM' 2='Solid tumors SPM' 3='Non-melanoma skin SPM' -9 = ' Not Applicable'
35	SPMfup_m	Num	Follow-up Time for all SPM Events (Months)	
36	adjSPMfup_m	Num	Follow-up Time for SPM (Months), excluding basal and non-melanoma cancer	
37	OCfactf_1000	Num	FACT Functional QOL Score at Baseline	
38	OCfactf_1007	Num	FACT Functional QOL Score at Treatment Cycle 7	
39	OCfactf_1012	Num	FACT Functional QOL Score at Treatment Cycle 12	
40	OCfactf_1018	Num	FACT Functional QOL Score at Treatment Cycle 18	
41	OCfactf_1897	Num	FACT Functional QOL Score at the End of Tx	
42	OCfactf_1024	Num	FACT Functional QOL Score at Treatment Cycle 24	
43	OCfactmtoi_1000	Num	FACT MM TOI QOL Score at Baseline	
44	OCfactmtoi_1007	Num	FACT MM TOI QOL Score at Treatment Cycle 7	
45	OCfactmtoi_1012	Num	FACT MM TOI QOL Score at Treatment Cycle 12	
46	OCfactmtoi_1018	Num	FACT MM TOI QOL Score at Treatment Cycle 18	
47	OCfactmtoi_1897	Num	FACT MM TOI QOL Score at the End of Tx	
48	OCfactmtoi_1024	Num	FACT MM TOI QOL Score at Treatment Cycle 24	
49	OCfactp_1000	Num	FACT Physical QOL Score at Baseline	
50	OCfactp_1007	Num	FACT Physical QOL Score at Treatment Cycle 7	
51	OCfactp_1012	Num	FACT Physical QOL Score at Treatment Cycle 12	
52	OCfactp_1018	Num	FACT Physical QOL Score at Treatment Cycle 18	
53	OCfactp_1897	Num	FACT Physical QOL Score at the End of Tx	
54	OCfactp_1024	Num	FACT Physical QOL Score at Treatment Cycle 24	
55	OCfactntx_1000	Num	FACT-Ntx QOL Score at Baseline	
56	OCfactntx_1007	Num	FACT-Ntx QOL Score at Treatment Cycle 7	
57	OCfactntx_1012	Num	FACT-Ntx QOL Score at Treatment Cycle 12	
58	OCfactntx_1018	Num	FACT-Ntx QOL Score at Treatment Cycle 18	
59	OCfactntx_1897	Num	FACT-Ntx QOL Score at the End of Tx	
60	OCfactntx_1024	Num	FACT-Ntx QOL Score at Treatment Cycle 24	
61	OCfactntxtoi_1000	Num	FACT-Ntx TOI QOL Score at Baseline	
62	OCfactntxtoi_1007	Num	FACT-Ntx TOI QOL Score at Treatment Cycle 7	
63	OCfactntxtoi_1012	Num	FACT-Ntx TOI QOL Score at Treatment Cycle 12	
64	OCfactntxtoi_1018	Num	FACT-Ntx TOI QOL Score at Treatment Cycle 18	
65	OCfactntxtoi_1897	Num	FACT-Ntx TOI QOL Score at the End of Tx	
66	OCfactntxtoi_1024	Num	FACT-Ntx TOI QOL Score at Treatment Cycle 24	
67	OCfactmm_1000	Num	FACT MM QOL Score at Baseline	
68	OCfactmm_1007	Num	FACT MM QOL Score at Treatment Cycle 7	
69	OCfactmm_1012	Num	FACT MM QOL Score at Treatment Cycle 12	
70	OCfactmm_1018	Num	FACT MM QOL Score at Treatment Cycle 18	
71	OCfactmm_1897	Num	FACT MM QOL Score at the End of Tx	
72	OCfactmm_1024	Num	FACT MM QOL Score at Treatment Cycle 24	
73	ind_primary	Num	Included in Primary Analyses	1 = 'No' 2 = 'Yes'

\* Due to de-identification procedures, it will not be possible to fully replicate age-related values in Table 1 of the primary publication for this trial.